28822-58-4

基本信息
3-異丁基-1-甲基黃嘌呤
1-甲基-3-異丁基黃嘌呤
3-ISOBUTYL-1-METHYL-2,6(1H,3H)-PURINEDIONE
3-ISOBUTYL-1-METHYLXANTHINE
3-ISOBUTYL-I-METHYLXANTHINE
IBMX
MIX
1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-3-(2-methylpropyl)-
3,7-dihydro-1-methyl-3-(2-methylpropyl)-1h-purine-6-dione
3-Isobutyl-1-methyl-3,7-dihydro-1H-purine-2,6-dione
3-Isobutyl-1-methylanxthine
3-isobutyl-1-methyl-xanthin
IMX
Isobutylmethylxanthine
Methylisobutylxanthine
SC 2964
Xanthine, 3-Isobutyl-1-methyl-
3,7-Dihydro-1-methyl-3-(2-methylpropyl)-1H-purine-2,6-dione
3,7-dihydro-3-isobutyl-1-methyl-1H-purine-2,6-dione
3-ISOBUTYL-1-METHYLXANTHINE SIGMAULTRA
Isobutyl-1-methylxanthine
物理化學(xué)性質(zhì)
應(yīng)用領(lǐng)域
知名試劑公司產(chǎn)品信息
報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
2025/02/08 | HY-12318 | 3-異丁基-1-甲基黃嘌呤 IBMX | 28822-58-4 | 5 mg | 181元 |
2025/02/08 | HY-12318 | 3-異丁基-1-甲基黃嘌呤 IBMX | 28822-58-4 | 10mM * 1mLin DMSO | 199元 |
2025/02/08 | HY-12318 | 3-異丁基-1-甲基黃嘌呤 IBMX | 28822-58-4 | 10 mg | 240元 |
常見問題列表
Target | Value |
PDE3
() | 6.5 μM |
PDE4
() | 26.3 μM |
PDE5
() | 31.7 μM |
At 100 μM, KMUP-1 (a xanthine derivative) and IBMX are the most effective at inducing tracheal relaxation; the magnitude of the relaxation responses induced by KMUP-1 and IBMX are not significantly different. IBMX (100 μM) activates renal outer medullary K + (ROMK) channels (n=6, P<0.05) and prevents further channel activation by ANG II (n=6, P=NS) or cGMP. Of note is that pretreatment of cortical collecting duct (CCDs) isolated from high-K + (HK)-fed rats with IBMX (100 μM) for 20 min leads to a significant increase in tubular cAMP content to 1.43±0.35 pg/mm tubule length (n=14) compare with that measured in vehicle-treated controls (0.61±0.13 pg/mm tubule length, n=12, P<0.05).
IBMX, a non-selective PDE inhibitor significantly decreases the liver glycogen storage (mg/g, IBMX 22±1.5 P<0.001). In comparison with the control group, IBMX and mc5 significantly increase plasma glucose (blood glucose, mg/dl, control=141±3, IBMX=210±17 P<0.001 and mc5=191±13 P<0.01) while other test compounds (mc1, mc6, MCPIP and Win 47203) do not produce significant effect (control=141±3, mc1 160±7, mc6 175±9, MCPIP 179±8 and Win 47203 116±2 P>0.05) also mc2 does not change plasma glucose (control=141±3 and mc2=145±5). IBMX has the highest efficacy on increasing plasma glucose. Treatments with IBMX and Apocynin significantly decrease cold-induced elevation of right ventricular (RV) systolic pressure (23.5±1.8 and 24.2±0.6 mmHg, respectively) although they do not decrease RV pressure to the warm control levels. IBMX or Apocynin significantly reduces medial layer thickness (19.0±0.9, and 16.9±0.8 μm, respectively) and increases lumen diameter (62.7±4.2, and 59.5±4.3 μm, respectively) of small PAs in cold-exposed rats.